

## CPT<sup>®</sup> Editorial Summary of Panel Actions June 2017

## **CPT® Editorial Summary of Panel Action June 2017**

Please be aware that this action is a reflection of the discussion at the most recent Panel meeting. Disclosure of Panel action and deliberation is limited to the information contained in this Summary of Actions. Premature release of coding information other than that contained in this document is prohibited under the <a href="CPT Confidentiality Agreement">CPT Confidentiality Agreement</a>. Codes are not assigned, nor exact wording finalized, until just prior to publication. Release of more specific CPT® code set information is timed with the release of the entire set of coding changes in the CPT publication.

If an applicant or other interested party believes an action of the CPT Editorial Panel was in error, that individual or entity may request reconsideration of the Panel action. An "interested party" is an individual or entity that may potentially be impacted by the Panel's decision, regardless of whether they participated in the Panel's original consideration of the matter.

**Submitting the Request:** Requests for reconsideration must be received by AMA staff no later than midnight, Central, July 14, 2017, fourteen (14) days after the published posting date (June 30, 2017) of the Summary Grid of Editorial Panel Actions on the CPT website <a href="https://www.ama-assn.org/go/cpt">www.ama-assn.org/go/cpt</a>. The request should contain (1) the specific action requested for reconsideration; (2) the basis for the reconsideration request; and (3) all information relevant to the matter, including any literature (whether favorable or adverse) related to the requestor's position. Requests for reconsideration and relevant information must be in writing and submitted to:

Marie Mindeman
Director, CPT Coding, Editorial and Regulatory Services
American Medical Association
AMA Plaza
330 N. Wabash Ave., Suite 39300
Chicago, IL 60611-5885

Participation by Interested Parties: The receipt of a request for reconsideration, the identity of the party seeking such, and a brief summary of the basis for the reconsideration request will be noted in the summary grid of Editorial Panel actions for the agenda item. The applicant and interested parties are responsible for monitoring postings to the CPT website with respect to requests for reconsideration. CPT staff will make reasonable efforts to identify potentially interested parties and notify them of the receipt of the request for reconsideration and the opportunity to be heard. An interested party seeking to comment on the request for reconsideration should submit its comments within fourteen (14) days of the posting of the notice (see deadline in Submitting the Request above) in the summary grid of Editorial Panel actions that a request for reconsideration has been received. Comments should include (i) a statement of the nature of the commenter's interest in the issue, (ii) the specific comment and reason for the comment, and (iii) all relevant material including any literature (whether favorable or adverse) related to the commenter's position. Comments should be submitted to the Director of CPT Editorial Research & Development at the address shown above. The applicant(s) who submitted the original code change proposal is automatically considered an interested party and will receive notice of any request for reconsideration submitted by another party.

Note: Codes that contain an 'X' (e.g., 1002X4, 234X2X, 0301XT) are placeholder codes that are intended, through the first three digits, to give readers an idea of the proposed placement in the code set of the potential code changes. These codes are not used for claims reporting and will be removed and not retained when the final CPT Datafiles are distributed on August 31st of each year. To report the services for 'X' codes, please refer to the actual codes as they appear in the CPT Datafiles publication distributed on or before August 31st of each year.

Tab #	Name	Code #	Description of Editorial Panel Action	Request for Reconsideration
6	Fine Needle Aspiration	10X10-10X19 10021 10022	Accepted addition of ten codes (10X10-10X19) to report fine needle aspiration procedures without imaging guidance and deletion of codes 10021, 10022.	
7	Skin Substitute Graft Guidelines	15002-15278	Accepted revision of the Skink Substitute Graft Guidelines to clarify that application of powder is not reported with the skin substitute graft codes.	
8	Knee Arthroplasty with Placement Kinetic Balance Sensor- WITHDRAWN			
9	Knee Arthrography Injection	27X69 27370	Accepted addition of code 27X69 to report injection procedure for knee arthrography or enhanced CT/MRI knee arthrography and deletion of code 27370	
10	PICC Line Procedures	36568 36569 36584 36X72 36X73 36X86	Postponed	
11	Implantation of Artificial Sphincter-Delete 46762	46762	Accepted deletion of code 46762	
12	Transcutaneous Neurostimulator (TENS)- Delete 64550	64550	Accepted deletion of code 64550	
13	Ultrasound of Extremity	76881 76882	Accepted revision of 76881 and 76882 to clarify the distinction between complete and limited studies	
14	Breast MRI with Computer- Aided Detection	77X49 77X50 77X51 77X52 77058 77059 0159T	Accepted addition of 77X49, 77X50, 77X51, 77X52 to bundle CAD with breast MRI without contrast and deletion of 0159T, 77058 and 77059	

Tab #	Name	Code #	Description of Editorial Panel Action	Request for Reconsideration
15	Tier 1 TGFBI Corneal Dystrophy	81X06	Rejected	
16	Tier 1 EZH2 Hematologic Neoplasm	81X07 81X08	Accepted addition of Tier 1 molecular pathology codes 81X07 and 81X08 to report EZH2 mutation gene analysis for hematologic neoplasms	
17	Tier 1 BTK and PLCG2 Chronic Lymphocytic Leukemia	81X09 81X10	Accepted addition of Tier 1 molecular pathology codes 81X09 and 81X10 to report BTK and PLCG2 mutation gene analysis for chronic lymphocytic leukemia	
18	Tier 1 SEPT9 Promoter Methylation Analysis 81327	81327	Accepted revision of Tier 1 molecular pathology code 81327 to specify promoter methylation analysis of the SEPT9 promoter gene with addition of definitions	
19	Tier 2 PRAME and LINC00518 Melanoma	81401	Accepted revision of Tier 2 molecular pathology test code 81401 with addition of PRAME and LINC00518 analyses	
20	GSP Panethnic Genetic Carrier Screening Panel	81X43	Accepted addition of GSP molecular pathology test code 81X43 for genomic testing for sever inherited conditions	
21	Rapid GI Pathogen Target Testing	87X08	Rejected	
22	Influenza Virus Vaccine with Preservative	90X78	Accepted addition of code 90X78 to report influenza virus vaccine for intramuscular use and revision of the CPT guidance for early	

Tab #	Name	Code #	Description of Editorial Panel Action	Request for Reconsideration
			release of codes	
23	Zoster Vaccine- WITHDRAWN			
24	Electroretinography-Full Field-92275 927X3	92275 927X3	Accepted addition of code 927X3 and guidelines and deletion of 92275 to report full-field electroretinography retinal evaluation test	
25	Electroretinography-Multi- Focal-927X4	03X1T	Accepted addition of Category III code 03X1T to report multifocal electroretinography retinal evaluation test	
26	Electroretinography-Pattern- 927X5	03X0T	Accepted addition of Category III code 03X0T to report pattern electroretinography retinal evaluation test	Request received to reconsider Editorial Panel decision to establish a Category III code for pattern electroretinography
27	Pulmonary Wireless Pressure Sensor Services	93X04 93X01	Postponed	
28	Transcatheter Closure of Patent Ductus Arteriosus	93568 93582	Accepted revision of add-on instruction for 93568	
29	Intraoperative Neurophysiologic Monitoring- WITHDRAWN			
30	Long Term EEG Monitoring		Postponed	
31	Neurostimulator Services	95X83 95X84 95X85 95X86 95X87 95X88 95970 95971 95972 95974 95975 95978 95979	Accepted addition of codes 95X83-95X87 to describe analysis and programming of implanted cranial nerve neurostimulator pulse generator, analysis, and programming of brain, neurostimulator pulse generator systems and analysis of stored neurophysiology recording data; revision of 95970, 95971, 95972 and introductory guidelines; and deletion of 95974, 95975, 95978	

Tab #	Name	Code #	Description of Editorial Panel Action	Request for Reconsideration
			and 95979	
32	Psychological and Neuropsychological Testing	96101 96102 96103 96111 96116 96118 96119 96120 963X0 963X1 963X2 963X3 963X4 963X5 963X5 963X6 963X7 963X8 963X8 963X9 96X10 96X11	Accepted addition of new subheadings and guidelines within the central nervous system assessments/tests sections and codes 963X0 -963X9 and 96X10-96X12 to differentiate technician administration of neuropsychiatric testing from physician/psychologist administration and assessment of testing; revision of 96116 and deletion of 96101-96103, 96111, 96118, 96119, 96120.	
33	Cat II Changes for A1C and BP- WITHDRAWN			
34	Cat III Near-Infrared Spectroscopy	01X1T	Accepted addition of 01X1T to report near infrared spectroscopy studies of lower extremity wounds	
35	Cat III Adipose Tissue- Derived Cell Therapy	09X6T 09X7T	Accepted addition of codes 09X6T, 09X7T to report processing and injection of harvested cells.	
36	Cat III Convective Water Vapor Ablation of Prostate- WITHDRAWN			
37	Cat III Ablative Laser Wound Treatment	09X9T 01X0T	Accepted addition of Category III codes 09X9T and 01X0T to describe laser treatment of wounds	
38	Cat III Intraoperative Alignment of Intraocular Device		Rejected	Request received to reconsider Editorial Panel rejection of request for Category III code for intraocular device alignment

Tab #	Name	Code #	Description of Editorial Panel Action	Request for Reconsideration
39	Cat III HPV Extended Genotyping	02X1T	Accepted addition of 02X1T to describe HPV extended genotyping	
40	Cat III Noninvasive Estimated Coronary Fractional Flow Reserve- (FFR)	02X4T 02X5T 02X6T 02X7T	Accepted addition of Category III codes 02X4T -02X7T to describe non- invasive estimated coronary fractional flow reserve measurement derived from coronary computed tomography	
41	Cat III Donor Lung Assessment and Perfusion	01X2T 01X3T 01X4T	Accepted addition of Category III codes 01X2T-01X4T to describe ex vivo assessment and perfusion of cadaver lung	
42	Cat III Cardiac Phase Space Tomography (cPSTA)		Postponed	
43	Cat III Urethral Therapeutic Drug Delivery	02X0T	Accepted addition of Category III code 02X0T to describe urethral therapeutic drug delivery via urethral cystourethroscopy	
44	Cat III Diabetes Behavior Change Intervention	08X1T	Accepted addition of Category III code 08X1T to describe remote diabetes behavior counseling	
45	Cat III Mobile External ECG Event Recording Services	01X5T 01X6T	Accepted addition of Category III codes to report mobile external electrocardiography	
46	Telemedicine Transition		Postponed	
47	Appendix P Revision- WITHDRAWN			
48	Cat II - Additional Application Revisions		Accepted revision of the Category II code change application	
49	Qualified Health Care Professional		Accepted revision of the introductory code set text	

Tab #	Name	Code #	Description of Editorial Panel Action	Request for Reconsideration
50	Patient Relationship Modifiers	X10-X14	Accepted addition of modifiers X10-X14 to describe clinician relationship to patient services	
51	Alternative Payment Model Modifiers		Postponed	
52	Vascular Family Definitions		Postponed	
53	Category I/III Application		Accepted revision of the Category I/III code change application	
54	Attended Surveillance		Postponed	
55	Proprietary Laboratory Analyses (PLA) Standard Operating Procedure Revisions		Accepted revision of the Proprietary Laboratory Analyses SOP	
56	HCPAC Structure and Function Revisions		Accepted revision of the HCPAC Structure and Function document	
57	Transurethral Thermotherapy WITHDRAWN			
58	Proprietary Laboratory Analyses (PLA) Application and Process Revisions		Accepted revision of the Proprietary Laboratory Analyses application	
59	Chemotherapy Modifier		Rejected	
60	Guidance for Advisors		Accepted revision of the Guidance for Advisors document	
61	SmartApp Editorial Changes for Category I and Category III Application		Informational	
62	SmartApp Editorial Changes for Category I Short-RUC Application		Informational	
63	SmartApp Editorial Changes for MAAA Application		Informational	
64	SmartApp Editorial Changes for Path and Lab Application		Informational	

Tab #	Name	Code #	Description of Editorial Panel Action	Request for Reconsideration
EC-B	October 2016 Executive Committee Minutes		Accepted editorial revision of 95930, revision of 946X2 to include electrocardiographic recordings	
EC-C	Electroretinography		Informational	
EC-D	EVAR	37221 37223	Accepted revision of instructions for codes 37221 and 37223	
EC-E	Family Psychotherapy	99354 90846	Accepted editorial revision of the prolonged service instructions for reporting with 90846	
EC-F	Literature Requirements for Legacy Services – WITHDRAWN			
EC-G	Moderate Sedation Vascular Correction for 2017	37184	Accepted editorial revision of the instruction following 37184	
EC-H	Psychiatric Collaborative Care Management Table		Rejected	
EC-I	Rehabilitative and Habilitative Services - Editorial Revisions	X8 X9	Accepted editorial revision of modifier descriptors for consistency with nomenclature	
EC-J	Required Category I Code Criteria		Accepted editorial revision of the Category I criteria	
EC-K	CPT Assistant Editorial Board Report		Informational	
EC-L	RUC Report Issue #1		Informational	
Issue #1	Chronic Care Management (994X7)			
EC-L Issue #2	RUC Report Issue #2 Emerging Technology Services Workgroup		Informational	
EC-L Issue #3	RUC Report Issue #3 Sleep Testing (95801)		Informational	

Tab #	Name	Code #	Description of Editorial Panel Action	Request for Reconsideration
EC-L Issue #4	RUC Report Issue #4 Continuous Glucose Monitoring (9525X)	9525X	Accepted revision of instructions for code 9525X; and recommended publication of new and revised codes for CPT 2018	
EC-L Issue #5	RUC Report Issue #5 Structural Allograft (209X3, 209X4, 209X5)	209X3 209X4 209X5	Accepted revision of instructions for codes 209X3, 209X4, 209X5	
EC-L Issue #6	RUC Report Issue #6 Vignette Typical Patient Format		Informational	
EC-L Issue #7	RUC Report Issue #7 Fluoroscopy(76001)		Informational	
EC-M	Vaccine Coding Change Application		Informational	
EC-N	Zoster Vaccine Editorial Revision of 906X5	906X5	Accepted editorial revision of 906X5	
EC-O	Laparoscopic Uterine Fibroid Ablation Code Placement	58674	Accepted editorial placement revision of code 58674	
EC-P	Interested Party Definitions		Informational	
EC-Q	Continuous Glucose Monitoring		Referred to EC Tab L- Issue #4	